NASDAQ: MNKDMannkind Corp Stock
$4.18-0.01 (-0.24%)
Updated Apr 25, 2024
MNKD Price
$4.18
Fair Value Price
N/A
Market Cap
$1.13B
52 Week Low
$3.17
52 Week High
$5.75
P/E
-104.5x
P/B
-4.59x
P/S
4.89x
PEG
N/A
Dividend Yield
N/A
Revenue
$198.96M
Earnings
-$11.94M
Gross Margin
68.5%
Operating Margin
7.43%
Profit Margin
-6%
Debt to Equity
-2.93
Operating Cash Flow
$34M
Beta
1.14
Next Earnings
May 7, 2024
Ex-Dividend
N/A
Next Dividend
N/A
MNKD Overview
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how MNKD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MNKD is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
MNKD is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
MNKD's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more MNKD due diligence checks available for Premium users.
Be the first to know about important MNKD news, forecast changes, insider trades & much more!
MNKD News
Valuation
MNKD price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-104.5x
Industry
15.41x
Market
40.97x
MNKD price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-4.59x
Industry
5.8x
MNKD's financial health
Profit margin
Revenue
$58.5M
Net Income
$1.4M
Profit Margin
2.4%
MNKD's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
MNKD's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$475.2M
Liabilities
$721.4M
Debt to equity
-2.93
MNKD's short-term assets ($373.39M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MNKD's long-term liabilities ($617.24M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MNKD's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
MNKD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$21.7M
Investing
-$7.9M
Financing
$141.7M
MNKD's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MNKD vs Biotech Stocks
Mannkind Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.